Chen On, Mojahedi Azad
Divison of Cardiology, Stony Brook University Hospital Stony Brook, New York, The United States.
Department of Internal Medicine, Stony Brook University Hospital Stony Brook, New York, The United States.
Am J Cardiovasc Dis. 2024 Aug 25;14(4):196-207. doi: 10.62347/STFL9135. eCollection 2024.
Takotsubo cardiomyopathy (TCM) is a cardiac condition that is usually characterized by sudden heart failure (HF) or chest pain that resembles acute coronary syndrome (ACS). It is identified by severe systolic dysfunction of the left ventricle (LV) and can be caused by physical, medical, or emotional stress. The pathophysiological mechanisms leading to TCM have not yet been clearly determined. TCM is a complex condition to diagnose and may go undetected during cancer treatment due to the wide variety of cardiotoxic effects associated with antineoplastic therapies. Consequently, timely identification and effective treatment are critical to enhancing the prognosis. Nevertheless, TCM is a more prevalent condition in oncology than was previously believed; therefore, clinicians who treat cancer patients should consider it in their differential diagnosis. The purpose of this manuscript is to provide physicians with a summary of the available evidence regarding the ramifications of the association between TCM and cancer to aid in improving patient management.
应激性心肌病（TCM）是一种心脏疾病，通常表现为突发心力衰竭（HF）或类似急性冠状动脉综合征（ACS）的胸痛。它通过左心室（LV）严重收缩功能障碍来识别，可能由身体、医疗或情绪应激引起。导致TCM的病理生理机制尚未明确确定。TCM是一种难以诊断的复杂病症，由于抗肿瘤治疗相关的多种心脏毒性作用，在癌症治疗期间可能未被发现。因此，及时识别和有效治疗对于改善预后至关重要。然而，TCM在肿瘤学中比以前认为的更为普遍；因此，治疗癌症患者的临床医生在鉴别诊断时应考虑到这一点。本手稿的目的是为医生提供有关TCM与癌症关联后果的现有证据总结，以帮助改善患者管理。
